Oncimmune Holdings full year results and conference call

DirectorsTalk Interviews

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, states that it will be announcing its full year results for the year ended 31st May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at [email protected] or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

• The online presentation will be open to all existing shareholders and potential new investors.

• Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

• Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Oncimmune Holdings will automatically receive an invitation to the presentation.

Share on:

Latest Company News

Changing clinician behaviour reshapes commercial strategy for 2026

As clinician engagement becomes more digital and measurable, companies that act on behavioural data can improve targeting, reduce risk and strengthen competitive positioning in 2026.

Design priorities reshape kitchen investment landscape in 2026

2026 kitchen design trends show clear demand for practical features, natural materials and timeless styling in wet zones.

GCP Infra reports £853.8m portfolio and advances capital allocation plan

As at 31 December 2025, GCP Infra reported a NAV of 100.27p per share and a portfolio yield of 8.0% across 47 investments.

RTW Biotech Opportunities reports January NAV of US$2.37; sector activity builds

As at 31 January 2026, RTW Biotech Opportunities Ltd recorded an unaudited NAV of US$2.37 per share, reflecting a 3.6% monthly decline.

TwentyFour Income Fund reports 9.65% one-year NAV return to January 2026

TwentyFour Income Fund Limited has published its January 2026 factsheet, reporting a 9.65% one-year NAV total return and a current mark-to-market yield of 9.93% as at 30 January 2026.

Vp plc Earnings Reset Reflects Market Headwinds, Says Equity Development

Vp plc resets earnings expectations amid market headwinds, with Equity Development highlighting recovery potential and attractive sub 10x valuation.

    Search

    Search